查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602797

骨質疏鬆症藥物和骨折藥物市場：按藥物、給藥途徑和分銷分類 - 全球預測 2025-2030

Anti-Osteoporosis Therapy & Fracture Healing Market by Drug (Alendronate, Biophosphonates, Ibandronate), Route Of Administration (Injectable, Oral), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年骨質疏鬆和骨折藥物市場規模為138億美元，預計2024年將達到149.7億美元，複合年成長率為8.53%，2030年將達到244.8億美元。

抗骨質疏鬆治療和骨折治療市場著重於防止骨骼密度流失和改善骨折恢復的治療，特別是對於患有骨質疏鬆症（骨骼變弱的疾病）的患者。該市場是由人口老化加劇、骨質疏鬆症和相關骨折盛行率增加以及藥物治療和醫療設備的進步所推動的。這些治療方法對於降低與骨折相關的醫療費用和改善患者的生活品質至關重要。其應用範圍涵蓋醫院、整形外科診所和居家醫療，提供雙磷酸鹽、荷爾蒙補充療法和不斷成長的用於骨折癒合的生物材料等治療方法。關鍵的成長要素包括技術進步、骨骼健康意識的提高以及向微創治療的轉變。最新的機會在於個人化醫療和生技藥品，這得益於骨骼健康所涉及的遺傳因素和細胞機制的持續研究。公司可以透過策略夥伴關係、研發投資來利用這些趨勢。然而，市場面臨著治療成本上升、潛在的治療副作用、嚴格的監管核准以及來自替代療法和補充品的競爭等挑戰。需要技術創新的領域包括開發新的藥物傳輸系統、組織工程以及以幹細胞和生長因子為重點的再生醫學技術。此外，用於早期檢測骨質疏鬆症的診斷工具的改進提供了巨大的業務成長潛力。該市場高度動態，其特點是密集的研發和不斷變化的監管環境，要求公司保持敏捷性和適應性。在這種環境下，採取積極主動的策略來解決消費者教育方面的差異，同時創造具有成本效益、安全且高效的解決方案，對於成功至關重要。相關人員必須培養與醫療保健提供者和政策制定者的關係，以促進患者獲得治療並支持治療計劃中的明智決策。

主要市場統計
基準年[2023] 138億美元
預測年份 [2024] 149.7億美元
預測年份 [2030] 244.8億美元
複合年成長率（%） 8.53%

市場動態：快速發展的骨質疏鬆症和骨折藥物市場的關鍵市場洞察

供需的動態交互作用正在改變骨質疏鬆症和骨折藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 世界老年人口的增加
    • 由於快速都市化和生活方式的改變，骨骼疾病增加
    • 女性停經後骨質疏鬆症增加
  • 市場限制因素
    • 抗骨質疏鬆和骨折治療藥物高成本
  • 市場機會
    • 新藥引進的研發成長
    • 提高對骨質疏鬆症及其對健康影響的認知
  • 市場挑戰
    • 與抗骨質疏鬆藥物和骨折癒合相關的併發症和副作用

波特五力：駕馭骨質疏鬆症與骨折藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解骨質疏鬆藥物和骨折藥物市場的外部影響

外部宏觀環境因素在塑造骨質疏鬆藥物和骨折藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解骨質疏鬆症治療和骨折治療藥物市場的競爭狀況

骨質疏鬆症藥物和骨折治療藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣骨質疏鬆藥物和骨折藥物市場供應商的績效評估

FPNV定位矩陣是評估骨質疏鬆藥物和骨折藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，以規劃骨質疏鬆症和骨折治療市場的成功之路

對骨質疏鬆症藥物和骨折治療藥物市場進行策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地人口老化仍在持續
      • 由於快速的都市化和生活方式的改變，

骨病的發生

      • 女性停經後骨質疏鬆症發生率增加
    • 抑制因素
      • 骨質疏鬆症和骨折藥物的高昂費用
    • 機會
      • 擴大新藥引進的研究與開發
      • 持續認知骨質疏鬆症及其對健康的影響
    • 任務
      • 與骨質疏鬆藥物和骨折癒合相關的併發症和副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按藥物分類的骨質疏鬆症治療藥物和骨折治療藥物市場

  • 阿崙膦酸鈉
  • 生物磷酸鹽
  • Ibandronate sodium
  • 利塞膦酸鹽
  • 選擇性雌激素受體調節
    • Raloxifene
    • 鍶蘭雷特
  • Zoledronic acid

第7章骨質疏鬆藥物和骨折藥物市場：依給藥途徑

  • 可注射的
  • 口服

第8章 骨質疏鬆症治療藥物和骨折治療藥物市場經銷商

  • 藥局
  • 電子商務市場
  • 醫院
  • 私人診所
  • 零售藥房

第9章北美和南美骨質疏鬆和骨折藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太骨質疏鬆藥物與骨折藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的骨質疏鬆和骨折藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Healthy Life Pharma Pvt. Ltd.
  • Johnson & Johnson Services, Inc.
  • Manus Aktteva Biopharma LLP
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Salvavidas Pharmaceutical Private Limited
  • Sanofi SA
  • Taj Pharmaceuticals
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceuticals Industries Ltd
Product Code: MRR-CA17E905EAC5

The Anti-Osteoporosis Therapy & Fracture Healing Market was valued at USD 13.80 billion in 2023, expected to reach USD 14.97 billion in 2024, and is projected to grow at a CAGR of 8.53%, to USD 24.48 billion by 2030.

The anti-osteoporosis therapy and fracture healing market focuses on treatments that prevent bone density loss and improve recovery from bone fractures, especially for individuals with osteoporosis, a condition that weakens bones. This market is driven by a rising aging population, increased prevalence of osteoporosis and associated fractures, and advancements in pharmaceutical therapies and medical devices. These therapies are essential for reducing healthcare costs associated with fractures and improving the quality of life for patients. Their application spans hospitals, orthopedic clinics, and home healthcare, offering treatments like bisphosphonates, hormone replacement therapies, and growth in biomaterials used in fracture healing. Key growth influences include technological advancements, increased awareness about bone health, and a shift towards minimally invasive treatments. Latest opportunities lie in personalized medicine and biologics, driven by ongoing research on genetic factors and cellular mechanisms involved in bone health. Companies can capitalize on these trends through strategic partnerships, research, and development investment. However, the market faces challenges, such as high treatment costs, potential side effects of therapies, stringent regulatory approvals, and competition from alternative therapies and supplements. Areas ripe for innovation include the development of novel drug delivery systems, tissue engineering, and regenerative medicine techniques focusing on stem cells and growth factors. Additionally, improving diagnostic tools for early osteoporosis detection can offer substantial business growth potential. The market is highly dynamic, characterized by intensive R&D and evolving regulatory landscapes, requiring companies to remain agile and adaptive. Proactive strategies producing cost-effective, safe, and efficient solutions while addressing consumer education gaps are crucial for thriving in this environment. Stakeholders need to foster relationships with healthcare providers and policymakers to facilitate patient access and support informed decision-making in treatment planning.

KEY MARKET STATISTICS
Base Year [2023] USD 13.80 billion
Estimated Year [2024] USD 14.97 billion
Forecast Year [2030] USD 24.48 billion
CAGR (%) 8.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Osteoporosis Therapy & Fracture Healing Market

The Anti-Osteoporosis Therapy & Fracture Healing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising geriatric population worldwide
    • Rapid urbanization coupled with changing lifestyle is increasing the occurrence of bone diseases
    • Growing incidences of postmenopausal osteoporosis in women
  • Market Restraints
    • High cost of the anti-osteoporosis medications & fracture healing treatments
  • Market Opportunities
    • Growing research and development in introduction of new drugs
    • Ongoing awareness of osteoporosis and its impact on health
  • Market Challenges
    • Complication and side effects related to with anti-osteoporosis medications & fracture healing

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Osteoporosis Therapy & Fracture Healing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Osteoporosis Therapy & Fracture Healing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Osteoporosis Therapy & Fracture Healing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Osteoporosis Therapy & Fracture Healing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Osteoporosis Therapy & Fracture Healing Market

A detailed market share analysis in the Anti-Osteoporosis Therapy & Fracture Healing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Osteoporosis Therapy & Fracture Healing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Osteoporosis Therapy & Fracture Healing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Osteoporosis Therapy & Fracture Healing Market

A strategic analysis of the Anti-Osteoporosis Therapy & Fracture Healing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Osteoporosis Therapy & Fracture Healing Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Healthy Life Pharma Pvt. Ltd., Johnson & Johnson Services, Inc., Manus Aktteva Biopharma LLP, Merck & Co., Inc., Novartis AG, Pfizer Inc., Salvavidas Pharmaceutical Private Limited, Sanofi S.A., Taj Pharmaceuticals, Taj Pharmaceuticals Limited, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Anti-Osteoporosis Therapy & Fracture Healing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Alendronate, Biophosphonates, Ibandronate, Risedronate, Selective Oestrogen Receptor Modulators, and Zoledronic Acid. The Selective Oestrogen Receptor Modulators is further studied across Raloxifene and Strontium Ranelete.
  • Based on Route Of Administration, market is studied across Injectable and Oral.
  • Based on Distribution, market is studied across Drug Stores, E-Commerce Market, Hospitals, Private Clinics, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population worldwide
      • 5.1.1.2. Rapid urbanization coupled with changing lifestyle is increasing the

occurrence of bone diseases

      • 5.1.1.3. Growing incidences of postmenopausal osteoporosis in women
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of the anti-osteoporosis medications & fracture healing treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing research and development in introduction of new drugs
      • 5.1.3.2. Ongoing awareness of osteoporosis and its impact on health
    • 5.1.4. Challenges
      • 5.1.4.1. Complication and side effects related to with anti-osteoporosis medications & fracture healing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anti-Osteoporosis Therapy & Fracture Healing Market, by Drug

  • 6.1. Introduction
  • 6.2. Alendronate
  • 6.3. Biophosphonates
  • 6.4. Ibandronate
  • 6.5. Risedronate
  • 6.6. Selective Oestrogen Receptor Modulators
    • 6.6.1. Raloxifene
    • 6.6.2. Strontium Ranelete
  • 6.7. Zoledronic Acid

7. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Distribution

  • 8.1. Introduction
  • 8.2. Drug Stores
  • 8.3. E-Commerce Market
  • 8.4. Hospitals
  • 8.5. Private Clinics
  • 8.6. Retail Pharmacies

9. Americas Anti-Osteoporosis Therapy & Fracture Healing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Anti-Osteoporosis Therapy & Fracture Healing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Anti-Osteoporosis Therapy & Fracture Healing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Eli Lilly and Company
  • 3. F. Hoffmann-La Roche Ltd.
  • 4. GlaxoSmithKline plc
  • 5. Healthy Life Pharma Pvt. Ltd.
  • 6. Johnson & Johnson Services, Inc.
  • 7. Manus Aktteva Biopharma LLP
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. Salvavidas Pharmaceutical Private Limited
  • 12. Sanofi S.A.
  • 13. Taj Pharmaceuticals
  • 14. Taj Pharmaceuticals Limited
  • 15. Teva Pharmaceuticals Industries Ltd

LIST OF FIGURES

  • FIGURE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BIOPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STRONTIUM RANELETE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY E-COMMERCE MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE OESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 194. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2023